FDA to Review AVT02, a High Concentration Biosimilar to Adalimumab
AVT02 is a proposed biosimilar to Humira® (adalimumab) with high concentration (100mg/mL) dosage forms.
Psoriasis
RediTrex Now Available for RA, pJIA, Psoriasis Treatment
RediTrex is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis.
Deucravacitinib Shows Superiority to Apremilast in Psoriasis Trial
A phase 3 trial evaluating the efficacy and safety of deucravacitinib (BMS-986165; Bristol Myers Squibb), a novel, oral, selective TYK2 inhibitor, for the treatment of patients with moderate to severe plaque psoriasis met both co-primary and secondary end points.
Enstilar Labeling Updated With Data on Long-Term Use in Plaque Psoriasis
The update was based on data from the phase 3 PSO-LONG trial, a randomized, double-blind, vehicle-controlled study that evaluated the long-term use of Enstilar Foam in 545 adults.
Bimekizumab Under Review for Plaque Psoriasis
The BLA is supported by data from the phase 3 BE VIVID, BE READY, and BE SURE studies.
Shift Seen to Newer Agents to Treat Psoriasis
Biologics and small molecule inhibitors increasingly used for treatment of newly diagnosed psoriasis.
Tapinarof Cream Looks Promising for Plaque Psoriasis
The double-blind, vehicle-controlled studies (PSOARING 1 and PSOARING 2) assessed the efficacy and safety of tapinarof in 1025 patients aged 18 to 75 years with plaque psoriasis.
Stelara Approved for Pediatric Plaque Psoriasis
The approval of ustekinumab in pediatric patients was based on data from a phase 3 open-label, single-arm study (CADMUS Junior).
Bimekizumab Bests Secukinumab in Plaque Psoriasis Trial
Positive results were announced from a phase 3b study comparing bimekizumab (UCB) to secukinumab for the treatment of moderate to severe plaque psoriasis.
Wynzora Cream Approved for Plaque Psoriasis
Wynzora is a combination of calcipotriene, a synthetic vitamin D3 analogue, and betamethasone dipropionate, a corticosteroid, which utilizes the Company’s proprietary PAD Technology platform enabling stability of both agents in an aqueous formulation.
